



DISA Limited  
(Company Registration No. 197501110N)  
(Incorporated in the Republic of Singapore)

## **NEWS RELEASE:**

# **Digital Life Line Pte. Ltd. Signed MOU with Medical Saigon Group for the Trial Deployment of Automated Visual Acuity Test Device and AI-Based Retinal Imaging Solution in Vietnam**

**SINGAPORE – 24 June, 2024** — DISA Limited (the “**Company**”) is pleased to share that its subsidiary company, Digital Life Line Pte. Ltd. (“**DLL**”), has announced today on the signing of a Memorandum of Understanding (“**MOU**”) with Medical Saigon Group (“**MSG**”) that involves the trial deployment of its Automated Visual Acuity Test Device (“**AVAT**”) and AI-based retinal imaging solution (“**AI-VI**”) at multiple MSG hospitals in Vietnam.

MSG is one of the largest private hospital chains in Vietnam with a total 13 hospitals throughout Vietnam, including 8 ophthalmology hospitals in Hanoi, Vinh, Nha Trang, Ho Chi Minh City, Can Tho, and 5 general hospitals in Hà Tĩnh, Quảng Nam, Phan Rang and Nha Trang.


Over the past 17 years, MSG has been offering eye examination, refractive surgery, cataract surgery, glaucoma surgery, corneal transplant surgery, aesthetic shaping and general disease treatments, to more than 5.2 million patients. To-date, its hospitals have successfully performed surgery for more than 500,000 patients and have more than 1,600 medical staff.

In January 2024, global investment firm KKR & Co., an American private equity firm, became the largest shareholder of MSG. With KKR’s investment and partnership, MSG will be able to accelerate their growth to reach more patients, deliver better patient outcomes, and expand their footprint across Vietnam.

## **Automated Visual Acuity Test Device (“AVAT”)**

Developed by the Department of Ophthalmology at the National University Hospital (“**NUH**”) and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore (“**NUS Medicine**”), AVAT addresses the increasing demand to decentralise the existing care model of conducting eye screening and monitoring of eye diseases. By incorporating automation and digitalisation, AVAT provides for a more efficient, high-quality vision testing workflow with minimal costs and manpower resources.

*A portable, tabletop device that allows for accurate, self-testing of visual acuity without the need for trained supervision to address staff shortage and space constraints.*



For the trial deployment with MSG, AVAT will be used to speed up visual acuity testing in both community and tertiary care settings.

### **AI-Based Retinal Imaging Solution (AI-VI)**

Developed and validated by a top ophthalmology research institution in Singapore, AI-VI, an AI-based retinal imaging solution, can quickly and accurately detect visual impairment, potentially allowing for earlier intervention and improved patient outcomes. This also creates an opportunity for DLL to develop a simple and efficient referral system for tertiary vision care.

Most deep learning models detect eye diseases without factoring the visual function status, leading to overfitting. This may result in excessive referrals of general eye pathology cases that do not require immediate treatment. In contrast, the AI-VI model includes the functional status of the individual's vision and can therefore identify eye diseases with substantial visual loss more concisely.

“The use of AI-VI, a retinal image deep-learning model, will boost targeted referrals to eye centres by allowing for the rapid identification of individuals with serious eye conditions in the absence of trained professionals.” **Mr. Eddie Chng, the Managing Director and Chief Executive Officer of the Group said**, “By alleviating the need for skilled staff, innovative tools like AI-VI will boost the reach of community screening and enable early detection and treatment of eye diseases.”

-----End-----

### **About DISA Limited (SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)**

DISA Limited, is a publicly traded company on the Singapore Catalist Stock Exchange. Together with our subsidiaries, the Group focuses on pioneering and adopting the latest technological innovations to enhance outcomes, reduce costs, and improve efficiencies within the healthcare and consumer industry.

Bringing scaled solutions that thrive in a changing world, we leverage on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalisation of product and services that optimises efficiency and quality standards in our targeted markets.

More information is available at [www.disa.sg](http://www.disa.sg).

*This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (“Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited.  
Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542  
Telephone number: +65 6232 3210*